On July 30, Sanofi announced its Q2 2020 financial results, reporting revenue of €8.207 billion, a decrease of 3.4%. Total revenue for the first half of the year amounted to €17.180 billion, representing a 1.6% increase.
Core product Dupixent achieved second-quarter sales of €858 million, a 70% increase, with first-half revenues totaling €1.634 billion, up 93.8%. Dupixent has currently been approved for the treatment of atopic dermatitis (AD) in adults in 44 countries and is expected to gain approval in an additional 54 countries by the end of 2020.
Dupixent has been approved in China for the treatment of adult atopic dermatitis (AD). Sanofi estimates that Dupixent will reach 50,000 patients in China in 2020 and 150,000 patients in 2022. The company plans to advocate for its inclusion in the National Reimbursement Drug List of China in 2021 and aims to obtain approval for five additional indications by 2025.
Impacted by China’s volume-based procurement policy, Sanofi’s sales revenue in the Chinese market amounted to €1.307 billion in the first half of 2020, a year-on-year decline of 12.4%; sales revenue in China for the second quarter stood at €627 million, down 10.2%.
In terms of specific products, Plavix and Aprovel®/Avapro recorded second-quarter sales in the Chinese market of €87 million (-58.2%) and €41 million (-44%), respectively. Amaryl’s second-quarter sales in the Chinese market amounted to €9 million (-69.7%).